YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Analysis on Statins for The Treatment of Bone Fracture

스타틴계 고지혈증치료제의 골절치료효과에 대한 분석

  • Published : 2009.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (Statins) are potent inhibitors of cholesterol biosynthesis. Cholesterol-lowering therapy using statins significantly reduces the risk of coronary heart disease. Various discovery of statins as bone anabolic agents has spurred a great deal of interest among both basic and clinical bone researchers. In-vitro and some animal studies suggest that statins increase the bone mass by enhancing bone morphogenetic protein-2 (BMP-2)-mediated osteoblast expression. Clinical and animal test results of statins focusing on the prevention and treatment of bone fractures was collected. Three independent literature searches were performed by using from January 1, 2002 to September 2008 for clinical and animal test results. Search term included statins, HMG-CoA reductase inhibitors, pleiotropic effects, fracture, osteoporosis and clinical and animal test. No consensus has been reached whether clinical use of statins has beneficial effects on bone health, partly due to lower statin concentrations because of first-pass metabolism by the liver. Experimental use of statins as stimulators of bone formation suggests that they may have widespread applicability in the field of orthopaedics. With their combined effects on osteoblasts and osteoclasts, statins have the potential to enhance resorption of synthetic materials and improve bone ingrowth. In conclusion, The use of statins in the prevention and treatment of bone fractures requires further study. But observational studies suggest that statins for decreasing bone fractures including osteoporosis have to be considered local direct administration like transdermal or subcutaneous type over oral adminstration.

Keywords

References

  1. Endo, A. : The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569 (1992)
  2. Richard, N. M., Glen, B., Jean, K. C., Alan, M. H., Thomas, T. N. and John, C. V. : Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen and oxygen by 13C NMR and mass spectrometry. J. Am. Chem. Soc. 107, 3694 (1985) https://doi.org/10.1021/ja00298a046
  3. Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A. and Blasetto, J. W. : Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152 (2003)
  4. Jones, P. H., Hunninghake, D. B., Ferdinand, K. C., Stein, E. A., Gold, A., Caplan, R. J. and Blasetto, J. W. : : Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther. 26, 1388 (2004) https://doi.org/10.1016/j.clinthera.2004.09.005
  5. Bocan, T. M. : Pleiotropic effects of HMG-CoA reductase inhibitors. Curr. Opin. Investig. Drugs 3, 1312 (2002)
  6. Shaw, S. M., Fildes, J. E., Yonan, N. and Williams, S. G. : Pleiotropic effects and cholesterol-lowering therapy. Cardiology 112, 4 (2008) https://doi.org/10.1159/000137692
  7. Wolozin, B., Wang, S. W., Li, N. C., Lee, A., Lee, T. A. and Kazis, L. E. : Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5, 20 (2007)
  8. Fried, L. F. : Effects of HMG-CoA reductase inhibitors(statins) on progression of kidney disease. Kidney Int. 74, 571 (2008) https://doi.org/10.1038/ki.2008.231
  9. Cruz, A. C. and Gruber, B. L. : Statins and osteoporosis: can these lipid-lowering drugs also bolster bones? Cleve. Clin. J. Med. 69, 277 (2002) https://doi.org/10.3949/ccjm.69.4.277
  10. Meier, C. R., Schlienger, R. G., Kraenzlin, M. E., Schlegel, B. and Jick, H. : HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283, 3205 (2000)
  11. Wang, P. S., Solomon, D. H., Mogun, H. and Avorn, J. : HMGCoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283, 3211 (2000) https://doi.org/10.1001/jama.283.24.3211
  12. Baldini, V., Mastropasqua, M., Francucci, C. M. and D'Erasmo, E. : Cardiovascular disease and osteoporosis. J. Endocrinol. Invest. 28, 69 (2005)
  13. Viccica, G., Vignali, E. and Marcocci, C. : Role of the cholesterol biosynthetic pathway in osteoblastic differentiation. J. Endocrinol. Invest. 30, 8 (2007)
  14. Ohnaka, K. and Takayanagi, R. : Statin and BMP. Clin. Calcium. 14, 286 (2004)
  15. Lee, O. K., Ko, Y. C., Kuo, T. K., Chou, S. H., Li, H. J., Chen, W. M., Chen, T. H. and Su, Y. : Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. Cell Biochem. 93, 917 (2004) https://doi.org/10.1002/jcb.20241
  16. Horiuchi, N. and Maeda, T. : Statins and bone metabolism. Oral Dis. 12, 85 (2006) https://doi.org/10.1111/j.1601-0825.2005.01172.x
  17. Ruiz-Gaspa, S., Nogues, X., Enjuanes, A., Monllau, J. C., Blanch, J., Carreras, R., Mellibovsky, L., Grinberg, D., Balcells, S., Dez-Perez, A. and Pedro-Botet, J. : Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J. Cell. Biochem. 101, 1430 (2007) https://doi.org/10.1002/jcb.21259
  18. Song, C., Wang, J., Song, Q., Li, X., Chen, Z., Ma, Q., Liu, Z., Jia, H. and Dang, G. : Simvastatin induces estrogen receptoralpha (ER-alpha) in murine bone marrow stromal cells. J. Bone Miner. Metab. 26, 213 (2008) https://doi.org/10.1007/s00774-007-0820-6
  19. Staal, A., Frith, J. C., French, M. H., Swartz, J., Gngr, T., Harrity, T. W., Tamasi, J., Rogers, M. J. and Feyen, J. H. : The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 18, 88 (2003) https://doi.org/10.1359/jbmr.2003.18.1.88
  20. Bharti, A. C., Takada, Y. and Aggarwal, B. B. : Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J. Immunol. 172, 5940 (2004) https://doi.org/10.4049/jimmunol.172.10.5940
  21. Ahn, K. S., Sethi, G., Chaturvedi, M. M. and Aggarwal, B. B. : Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int. J. Cancer 123, 1733 (2008) https://doi.org/10.1002/ijc.23745
  22. Gutierrez, G. E., Lalka, D., Garrett, I. R., Rossini, G. and Mundy, G. R. : Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos. Int. 17, 1033 (2006) https://doi.org/10.1007/s00198-006-0079-0
  23. Robert, H. and Knopp. : Drug Treatment of Lipid Disorders. N. Engl. J. Med. 341, 2020 (1999) https://doi.org/10.1056/NEJM199912233412617
  24. Majima, T., Shimatsu, A., Komatsu, Y., Satoh, N., Fukao, A., Ninomiya, K., Matsumura, T. and Nakao, K. : Short-term effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern. Med. 46, 1967 (2007) https://doi.org/10.2169/internalmedicine.46.0419
  25. Jadhav, S. B., Narayana Murthy, P. S., Singh, M. M. and Jain, G. K. : Distribution of lovastatin to bone and its effect on bone turnover in rats. J. Pharm. Pharmacol. 58, 1415 (2006) https://doi.org/10.1211/jpp.58.10.0017
  26. Bielinska, A. and Gluszko, P. : Statins - are they potentially useful in rheumatology? Pol. Arch. Med. Wewn. 117, 420 (2007)
  27. Kolanczyk, M., Khnisch, J., Kossler, N., Osswald, M., Stumpp, S., Thurisch, B., Kornak, U. and Mundlos, S. : Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Medicine 6, 21 (2008)
  28. Yaturu, S. : Skeletal effects of statins. Endocr. Pract. 9, 315 (2003) https://doi.org/10.4158/EP.9.4.315
  29. Svejda, P., Soska, V. and Soucek, M. : The impact of statin therapy on bone density changes in postmenopausal women. Vnitr. Lek. 53, 1064 (2007)
  30. Coons, J. C. : Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann. Pharmacother. 36, 3260 (2002)
  31. Cushenberry, L. M. and de Bittner, M. R. : Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann. Pharmacother. 36, 671 (2002) https://doi.org/10.1345/aph.1A072
  32. Gonyeau, M. J. : Statins and osteoporosis: a clinical review. Pharmacotherapy 25, 228 (2005) https://doi.org/10.1592/phco.25.2.228.56954
  33. Schlienger, R. G. and Meier, C. R. : HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture? Drugs Aging 20, 321 (2003) https://doi.org/10.2165/00002512-200320050-00002
  34. Yao, W., Farmer, R., Cooper, R., Chmielewski, P. A., Tian, X. Y., Setterberg, R. B., Jee, W. S. and Lundy, M. W. : Simvastatin did not prevent nor restore ovariectomy-induced bone loss in adult rats. J. Musculoskelet. Neuronal. Interact. 6, 277 (2006)
  35. Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M. and Gutierrez, G. : Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946 (1999) https://doi.org/10.1126/science.286.5446.1946
  36. Bone, H. G., Kiel, D. P., Lindsay, R. S., Lewiecki, E. M., Bolognese, M. A., Leary, E. T., Lowe, W. and McClung, M. R. : Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: A double-blind, placebo-controlled, dose-ranging trial. J. Clin. Endocrinol. Metab. 92, 4671 (2007) https://doi.org/10.1210/jc.2006-1909
  37. Tanriverdi, H. A., Barut, A. and Sarikaya, S. : Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 120, 63 (2005) https://doi.org/10.1016/j.ejogrb.2004.08.007
  38. Sirola, J., Sirola, J., Honkanen, R., Krger, H., Jurvelin, J. S., MenpP. and Saarikoski, S. : Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos. Int. 13, 537 (2002) https://doi.org/10.1007/s001980200070
  39. Funkhouser, H. L., Adera, T. and Adler, R. A. : Effect of HMGCoA reductase inhibitors (statins) on bone mineral density. J. Clin. Densitom. 5, 151 (2002) https://doi.org/10.1385/JCD:5:2:151
  40. Rejnmark, L., Buus, N. H., Vestergaard, P., Andreasen, F., Larsen, M. L. and Mosekilde, L. : Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur. J Clin. Invest. 32, 581 (2002) https://doi.org/10.1046/j.1365-2362.2002.01024.x
  41. Nichols, R., Hopman, W. M., Morton, A. R., Harman, G. J. and Holden, R. M. : Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients. Hemodial. Int. 12, 175 (2008)
  42. Rejnmark, L., Vestergaard, P. and Mosekilde, L. : Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif, Tissue Int. 79, 27 (2006) https://doi.org/10.1007/s00223-006-0024-4
  43. Richard, E., Scranton, M. D., Melissa, Y., Elizabeth, L., Daniel, S., David, G. and Michael, G. : Statin Use and Fracture Risk. Arch. Intern. Med. 165, 2007 (2005) https://doi.org/10.1001/archinte.165.17.2007
  44. Schoofs, M. W., Sturkenboom, M. C., van der Klift, M., Hofman, A., Pols, H. A. and Stricker, B. H. : HMG-CoA reductase inhibitors and the risk of vertebral fracture. J. Bone Miner. Res. 19, 152 (2004)
  45. LaCroix, A. Z., Cauley, J. A., Pettinger, M., Hsia, J., Bauer D. C., McGowan, J., Chen, Z., Lewis, C. E., McNeeley, S. G., Passaro, M. D. and Jackson, R. D. : Statin use, clinical fracture, and bone density in postmenopausal women: results from the women's health initiative observational study. Ann. Intern. Med. 139, 97 (2003) https://doi.org/10.7326/0003-4819-139-2-200307150-00009
  46. Julie, A. P., Mark, A. K., Margaret, J. H., Kerrie, M. S. and Geoffrey, C. N. : Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study. Arch. Intern. Med. 162, 537 (2002) https://doi.org/10.1001/archinte.162.5.537
  47. Ray, W. A., Daugherty, J. R. and Griffin, M. R. : Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj. Prev. 8, 276 (2002) https://doi.org/10.1136/ip.8.4.276
  48. Nyan, M., Sato, D., Oda, M., Machida, T., Kobayashi, H., Nakamura, T. and Kasugai, S. : Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect. J. Pharmacol. Sci. 104, 384 (2007) https://doi.org/10.1254/jphs.SC0070184
  49. De Leo, V., Morgante, G., la Marca, A., Lanzetta, D., Cobellis, L. and Petraglia, F. : Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol. Endocrinol. 17, 329 (2003)
  50. Adah, F., Benghuzzi, H., Tucci, M., Russell, G. and England, B. : Cholesterol production inhibitor (statin) increased bone healing in surgically created femoral defect in an animal model. Biomed. Sci. Instrum. 43, 95 (2007)
  51. Skoglund, B., Forslund, C. and Aspenberg, P. : Simvastatin improves fracture healing in mice. J. Bone Miner. Res. 17, 2004 (2002) https://doi.org/10.1359/jbmr.2002.17.11.2004
  52. Vickers, S., Duncan, C. A., Chen, I. W., Rosegay, A. and Duggan, D. E. : Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18, 138 (1990)
  53. Mauro, V. F. : Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet. 24, 195 (1993) https://doi.org/10.2165/00003088-199324030-00002
  54. Mauro, V. F. and MacDonald, J. L. : Simvastatin: a review of its pharmacology and clinical use. Dalian Inst. Chem. Phys. 25, 257 (1991)
  55. Skoglund, B. and Aspenberg, P. : Locally applied Simvastatin improves fracture healing in mice. BMC Musculoskelet. Disord. 8, 98 (2007) https://doi.org/10.1186/1471-2474-8-98
  56. Gaw, A., Packard, C. J. and Shepherd, J. : Statins; The HMGCoA Reductase Inhibitors in Perspective. 2nd edition. London, Martin Dunitz, p340 (2004)
  57. Lennernas, H. and Fager, G. : Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403 (1997) https://doi.org/10.2165/00003088-199732050-00005
  58. Garrett, I. R., Gutierrez, G. E., Rossini, G., Nyman, J., McCluskey, B., Flores, A. and Mundy, G. R. : Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J. Orthop. Res. 25, 1351 (2007) https://doi.org/10.1002/jor.20391
  59. Ma, B., Clarke, S. A., Brooks, R. A. and Rushton, N. : The effect of simvastatin on bone formation and ceramic resorption in a peri-implant defect model. Acta. Biomater. 4, 149 (2008) https://doi.org/10.1016/j.actbio.2007.05.004
  60. Serin-Kilicoglu, S. and Erdemli, E. : New addition to the statin's effect. J. Trauma 63, 187 (2007) https://doi.org/10.1097/01.TA.0000240974.07999.bc
  61. OzeI., KiliE., GmC. and Gze, F. : Effect of local simvastatin application on mandibular defects. J. Craniofac. Surg. 18, 546 (2007) https://doi.org/10.1097/scs.0b013e318052ff05
  62. von Knoch, F., Wedemeyer, C., Heckelei, A., Saxler, G., Hilken, G., Brankamp, J., Sterner, T., Landgraeber, S., Henschke, F., Ler, F. and von Knoch, M. : Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis. Biomaterials 26, 5783 (2005) https://doi.org/10.1016/j.biomaterials.2005.02.008
  63. Yazawa, H., Zimmermann, B., Asami, Y. and Bernimoulin, J. P. : Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J. Periodontol. 76, 295 (2005) https://doi.org/10.1902/jop.2005.76.2.295
  64. Wong, R. W. and Rabie, A. B. : Statin-induced osteogenesis uses in orthodontics: a scientific review. World J. Orthod. 7, 35 (2006)
  65. Moriyama, Y., Ayukawa, Y., Ogino, Y., Atsuta, I. and Koyano, K. : Topical application of statin affects bone healing around implants. Clin. Oral Implants Res. 19, 600 (2008) https://doi.org/10.1111/j.1600-0501.2007.01508.x
  66. Benoit, D. S., Nuttelman, C. R., Collins, S. D. and Anseth, K. S. : Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration. Biomaterials 27, 6102 (2006) https://doi.org/10.1016/j.biomaterials.2006.06.031
  67. Gutierrez, G. E., Edwards, J. R., Garrett, I. R., Nyman, J. S., McCluskey, B., Rossini, G., Flores, A., Neidre, D. B. and Mundy, G. R. : Transdermal lovastatin enhances fracture repair in rats. J. Bone Miner. Res. 23, 1722 (2008) https://doi.org/10.1359/jbmr.080603